Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Alphyn Biologics, Inc. logo — Alphyn develops first-in-class, multi-target therapeutics fo...

Alphyn Biologics, Inc.

Alphyn develops first-in-class, multi-target therapeutics for atopic dermatitis & other severe and common skin diseases

Founded 2019 United States United States 4 employees Series Unknown Total: $11.83M Health Care, Health and Wellness +2

General Information

Company Name Alphyn Biologics, Inc.
Founded Year 2019
Location United States United States +2
Employees 4
Industries Health Care, Health and Wellness, Life Sciences +1
Funding Stage Series Unknown
Social

Get notified when Alphyn Biologics, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Alphyn Biologics, Inc.

Alphyn Biologics, Inc. is a clinical-stage dermatology company with a focus on developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. The company's lead product candidate, AB-101a, has completed a Phase 2a clinical trial and is a topical treatment for atopic dermatitis (AD), the most common form of eczema. This product has demonstrated a strong safety profile and is uniquely designed to target AD's bacterial and immune system components, making it ideal for treating infected and non-infected AD. Alphyn's AB-101 platform has multiple bioactive compounds, allowing for multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics with potential safety, efficacy, and regulatory marketing authorization advantages. Founded in 2019, Alphyn Biologics is headquartered in the United States with locations in Annapolis, Maryland, Cincinnati, Ohio, and a wholly-owned subsidiary in Australia. The startup has raised approximately $6.7 million in funding, with the latest being a $3.30M Series A investment on 15 September 2022 led by Queen City Angels, Angel Physicians Fund, and Serial Stage Venture Partners. Alphyn's commitment to addressing unmet needs in dermatology through innovative therapeutics, along with its strong investor support and promising clinical progress, positions it well for future success in the Health Care and Pharmaceutical industries.

Taxonomy: Dermatology, Biopharmaceuticals, Clinical-stage, Therapeutics, Atopic Dermatitis, Eczema, Topical Treatment, Pharmaceutical Research, Bioactive Compounds, Drug Development, Immunology, Clinical Trials, Regulatory Approval, Start-up

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 04 Apr 2024
Venture Round •••••• - 24 May 2023
Series A •••••• 3
Investor Investor Investor
15 Sep 2022
Venture Round •••••• - 20 May 2022

Alphyn Biologics, Inc. Alternatives & Competitors

Alphyn Biologics, Inc. vs
Chemomab Therapeutics
Chemomab Therapeutics Israel

Developing innovative therapeutics for diseases at confluence of fibrosis and inflammation with high...

Post Ipo Equity
21 employees
Biotechnology, Health Care
Alphyn Biologics, Inc. vs
HOPO Therapeutics
HOPO Therapeutics United States

Harnessing heavy metals to improve human health

11 employees
Health Care
Alphyn Biologics, Inc. vs
BBB Therapeutics
BBB Therapeutics The Netherlands

Combines existing drugs with it's proprietary for enhanced drug delivery across the blood-brain barr...

Unknown
21 employees
Biopharma, Biotechnology

FAQ About Alphyn Biologics, Inc.

Alphyn develops first-in-class, multi-target therapeutics for atopic dermatitis & other severe and common skin diseases
Alphyn Biologics, Inc. was founded in 2019.
Alphyn Biologics, Inc. is headquartered in United States.
Alphyn Biologics, Inc. operates in the following industries: Health Care, Health and Wellness, Life Sciences, Pharmaceutical.
Alphyn Biologics, Inc. has approximately 4 employees.
Alphyn Biologics, Inc. has completed 4 funding rounds, raising a total of $11.83M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Alphyn Biologics, Inc. include Chemomab Therapeutics, HOPO Therapeutics, BBB Therapeutics, Freedom Biosciences, Amphivena Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alphyn Biologics, Inc. and Chemomab Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Alphyn Biologics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes